BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update Read more about BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update
BioNTech Completes Acquisition of InstaDeep Read more about BioNTech Completes Acquisition of InstaDeep
BioNTech to Report Second Quarter 2023 Financial Results and Operational Update on August 7, 2023 Read more about BioNTech to Report Second Quarter 2023 Financial Results and Operational Update on August 7, 2023
BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC Read more about BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC
Pfizer and BioNTech Submit Applications to U.S. FDA for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine Read more about Pfizer and BioNTech Submit Applications to U.S. FDA for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine
Pfizer and BioNTech Initiate Application to European Medicines Agency for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine Read more about Pfizer and BioNTech Initiate Application to European Medicines Agency for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine
Baroness Nicola Blackwood Member of the Compensation, Nominating and Corporate Governance CommitteeMember of the Product Committee Baroness Nicola Blackwood
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO Read more about BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
